(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded - 2Safeguarding Your Senior Protection Against Extortion and Tricks.
- 3Tech for Wellbeing: Applications and Devices for a Better You
- 4Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- 5Ancient Pompeii construction site reveals the process for creating Roman concrete
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- Nigeria’s return to Windsor castle signals new era in UK economic partnership
- Shrewd Home Gadgets to Save Energy
- Am I a Summer, or is this a scam? What I learned from color analysis.
- Two Passover initiatives target isolation and safety for Israel’s elderly
- 6 Famous Urban communities for Shopping on the planet
- NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
- The Manual for Decent European Urban communities in 2024
- AI’s errors may be impossible to eliminate – what that means for its use in health care
